BD and Opentrons Pioneering Automation in Single-Cell Research
BD and Opentrons Form Strategic Partnership
BD (Becton, Dickinson and Company) (NYSE: BDX) has teamed up with Opentrons Labworks, Inc. in a promising collaboration aimed at accelerating advances in single-cell multiomics. With a shared vision, these leading companies are set to integrate robotic automation into BD’s advanced single-cell instruments, which is expected to significantly enhance research capabilities in medical science.
Transforming Research through Automation
The integration of innovative robotics into BD’s single-cell multiomics systems is poised to streamline critical workflows, allowing researchers to automate intricate lab procedures. Dr. Ranga Partha, VP/GM of BD Biosciences, emphasized the importance of these advancements, stating, "By revealing the multiple layers of biological information within cells, automation can accelerate findings in areas such as oncology and immunology, thus advancing drug development."
Enhancing Workflow Efficiency
The collaboration will particularly focus on the BD Rhapsody™ System being paired with the Opentrons Flex® platform. Together, they aim to facilitate a streamlined, hands-free approach to single-cell experiments. This integration promises a more efficient workflow in labs, allowing scientists to focus on analysis rather than manual tasks.
Reducing Costs for Higher Accessibility
"By combining our expertise and technologies, we aim to create more cost-effective solutions that are accessible to various labs," said James Atwood, CEO of Opentrons. This partnership not only seeks to heighten the efficiency of research but also strives to ensure that cutting-edge sequencing technologies are within reach for all researchers, from academia to biopharma.
Upcoming Opportunities for Early Access
For labs eager to explore these advancements, early access opportunities will be unfolding soon. BD and Opentrons will showcase their joint efforts at the upcoming American Society of Human Genetics (ASHG) Annual Meeting, where attendees can engage directly with the innovations at their respective booths. This event is a prime opportunity to witness the future of lab automation in action.
About BD
BD is recognized globally as a leader in medical technology, striving to enhance healthcare delivery through innovative solutions. With a dedicated workforce of over 70,000, BD focuses on improving the safety and efficiency of clinical processes, as well as supporting healthcare providers in delivering optimal patient care. The company's commitment to collaboration is crucial in addressing pressing health challenges worldwide.
About Opentrons
Opentrons Labworks, Inc. stands at the forefront of lab automation technology. The organization is lauded for making robotics accessible and affordable for research institutions, enabling them to enhance productivity in R&D operations. Their pioneering Flex® platform represents a leap forward in open-source lab technologies, allowing labs to leverage AI tools in their operations.
Frequently Asked Questions
What is the main goal of the BD and Opentrons collaboration?
The primary aim is to integrate robotic automation into BD’s single-cell multiomics systems to enhance workflow efficiency and accelerate research outcomes.
How will automation impact single-cell multiomics research?
Automation will streamline crucial experimental steps, allowing researchers to conduct experiments faster, with greater reproducibility and less manual labor.
Where can researchers learn more about this partnership?
Information about the collaboration and early access opportunities will be available at the ASHG Annual Meeting and on the respective company websites.
What are some benefits of the integrated systems?
By integrating these systems, researchers will benefit from improved efficiency, cost-effectiveness, and accessibility to advanced technologies in lab settings.
How many systems have been deployed by Opentrons?
Opentrons has successfully deployed over 10,000 robotic systems across the globe, making them a significant player in the lab automation market.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.